5-amino-1mq nnmt inhibitor study Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target 5-Amino-1MQ: Benefits and Research Insights

For the beta diversity analyses, an analysis of similarities (ANOSIM) was performed on each of the distance/dissimilarity matrices to establish whether observed clustering by treatment group was statistically significant

This product is in its lyophilized powder form (freeze dried)

Shorten the cycle if: results have plateaued for 2+ weeks despite dose optimization, you are experiencing fatigue or other signs of potential receptor desensitization, or your goals have been achieved before the planned cycle end

Results demonstrated that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo. Critically, the peptide produced no clinically significant alterations in IGF-1 levels, no glucose intolerance or insulin resistance, and no anti-AOD9604 antibodies in any participant

Combined NNMT inhibitor treatment with reduced-calorie diet achieved 6.3 g cumulative weight loss versus 2.9 g with diet alone, and fat mass reduction was ten-fold greater with treatment (~29.3%) compared to diet switch alone (2.9%), while restoring fatty liver profiles to lean-control levels (Sampson et al., 2021)

AOD 9604 has been evaluated in rodent models of obesity